Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-06-09
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00006378
- Locations
- 🇺🇸
Morristown Memorial Hospital, Morristown, New Jersey, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University Hospitals of Cleveland, Cleveland, Ohio, United States
Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2004-06-09
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- SmithKline Beecham
- Target Recruit Count
- 40
- Registration Number
- NCT00003733
- Locations
- 🇬🇧
Mount Vernon Hospital, Northwood, England, United Kingdom
🇬🇧Charing Cross Hospital, London, England, United Kingdom
Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 12
- Registration Number
- NCT00005032
- Locations
- 🇺🇸
Central Illinois Hematology Oncology Center, Springfield, Illinois, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00004979
Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer
- Conditions
- Ovarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- University of Glasgow
- Target Recruit Count
- 1050
- Registration Number
- NCT00003998
- Locations
- 🇬🇧
C.R.C. Beatson Laboratories, Glasgow, Scotland, United Kingdom
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT00003401
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 38
- Registration Number
- NCT00004055
- Locations
- 🇺🇸
CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States
🇺🇸CCOP - Duluth, Duluth, Minnesota, United States
🇺🇸CentraCare Clinic, Saint Cloud, Minnesota, United States
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT00003399
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2004-05-27
- Last Posted Date
- 2011-04-20
- Lead Sponsor
- Theradex
- Target Recruit Count
- 100
- Registration Number
- NCT00003160
- Locations
- 🇺🇸
Akron General Medical Center, Akron, Ohio, United States
🇺🇸Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States
🇺🇸Harrington Cancer Center, Amarillo, Texas, United States
Paclitaxel in Treating Patients With Early-Stage Bladder Cancer
- Conditions
- Bladder Cancer
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Mary Babb Randolph Cancer Center at West Virginia University Hospitals
- Registration Number
- NCT00002917
- Locations
- 🇺🇸
West Virginia University Hospitals, Morgantown, West Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.